Catalyst Wire Dossier Catalyst Wire Dossier

AV-101

· VistaGen Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for AV-101, covering 2012-12-20 to 2022-03-02. Get the full timeline:

Most recent: Clinical Trial Update: Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder [Phase 2]

See pricing